Organon (OGN) Executive Chair buys 65,400 shares at $7.67

Organon & Co. (OGN) reported an insider purchase on a Form 4.

Rhea-AI Filing Summary

Organon & Co. (OGN) reported an insider purchase on a Form 4. Executive Chair and Director Carrie Smith Cox bought 65,400 shares of common stock on 11/12/2025 at a $7.6721 weighted average price.

The filing notes the shares were acquired in multiple trades within a price range of $7.6630 to $7.6899. Following the transaction, Cox beneficially owned 77,869 shares, held indirectly through an IRA.

Insider Trade Summary

Net Buyer: 65,400 shares

Net Buy 1 txn

Insider COX CARRIE SMITH

Role Executive Chair

Bought 65,400 shs ($502K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	65,400	$7.6721	$502K

Holdings After Transaction: Common Stock — 77,869 shares (Indirect, IRA)

Footnotes (1)

1. F1. The price reported is a weighted average price of $7.6721. These shares were purchased in multiple transactions at prices ranging from $7.6630 to $7.6899, inclusive. The reporting person undertakes to provide to Organon & Co. ("Organon"), any security holder of Organon, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

FAQ

What insider transaction was reported for OGN?

A Form 4 shows Executive Chair and Director Carrie Smith Cox purchased 65,400 shares of Organon common stock.

What was the purchase price disclosed for OGN shares?

The filing lists a $7.6721 weighted average purchase price, with trades from $7.6630 to $7.6899.

When did the OGN insider purchase occur?

The transaction date is 11/12/2025.

How many OGN shares does the insider own after the trade?

Beneficial ownership after the transaction is 77,869 shares.

Is the ownership direct or indirect for the reported OGN shares?

The shares are held indirectly via an IRA.

Did the filing report any derivative securities for OGN?

No derivative securities are listed in the provided section of the filing.

What roles does the reporting person hold at OGN?

Carrie Smith Cox is disclosed as Executive Chair and Director.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/13/2025 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

COX CARRIE SMITH

(Last) (First) (Middle)

C/O ORGANON & CO.

30 HUDSON STREET, FLOOR 33

(Street)

JERSEY CITY NJ 07302

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Organon & Co. [ OGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Executive Chair

3. Date of Earliest Transaction (Month/Day/Year)
11/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/12/2025		P		65,400	A	$7.6721(1)	77,869	I	IRA

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported is a weighted average price of $7.6721. These shares were purchased in multiple transactions at prices ranging from $7.6630 to $7.6899, inclusive. The reporting person undertakes to provide to Organon & Co. ("Organon"), any security holder of Organon, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Tarnetta V. Jones, as Attorney-in-Fact for Carrie Smith Cox	11/13/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.